Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2773-2776

  Barbour, April ^a   Schmidt, Stephan ^a   Sabarinath, Sreedharan Nair ^a   Grant, Maria ^a   Seubert, Christoph ^b   Skee, Donna ^c   Murthy, Bindu ^c   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR; CEFIXIME; CEFPIROME; CEFPODOXIME; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKELETAL MUSCLE; SKIN INFECTION; SOFT TISSUE INFECTION; SUBCUTANEOUS FAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADIPOSE TISSUE; ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICRODIALYSIS; MUSCLE, SKELETAL; YOUNG ADULT;

EID: 67649950669     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01409-08     Document Type: Article

References (25)

1. Center for Drug Evaluation and Research. 2003. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD.
2. Chaurasia, C. S., M. Muller, E. D. Bashaw, E. Benfeldt, J. Bolinder, R. Bullock, P. M. Bungay, E. C. DeLange, H. Derendorf, W. F. Elmquist, M. Hammarlund-Udenaes, C. Joukhadar, D. L. Kellogg, Jr., C. E. Lunte, C. H. Nordstrom, H. Rollema, R. J. Sawchuk, B. W. Cheung, V. P. Shah, L. Stahle, U. Ungerstedt, D. F. Welty, and H. Yeo. 2007. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm. Res. 24:1014-1025.
3. Craig, W. A. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl. 3):S233-S237.
4. Craig, W. A. 2002. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-22. In D. H. Nightingale, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Informa Healthcare, Inc., New York, NY.
5. Craig, W. A., and D. R. Andes. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496.
6. Dehghanyar, P., C. Burger, M. Zeitlinger, F. Islinger, F. Kovar, M. Muller, C. Kloft, and C. Joukhadar. 2005. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob. Agents Chemother. 49:2367-2371.
7. de La Pena, A., M. Brunner, H. G. Eichler, E. Rehak, J. Gross, U. Thyroff-Friesinger, M. Muller, and H. Derendorf. 2002. Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans. J. Clin. Pharmacol. 42:403-411.
8. European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medicinal Products. 27 July 2000, posting date. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. European Agency for the Evaluation of Medicinal Products London, United Kingdom. http://www.emea.europa.eu/pdfs/human/ ewp/265599en.pdf.
9. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
10. Hollenstein, U., M. Brunner, B. X. Mayer, S. Delacher, B. Erovic, H. G. Eichler, and M. Muller. 2000. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin. Pharmacol. Ther. 67:229-236.
11. Janssen-Ortho, Inc. 2008. Zeftera product monograph. Janssen-Ortho, Inc., Toronto, Ontario, Canada. http://www.janssen-ortho.com/JOI/ pdf-files/Zeftera-E.pdf.
12. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
13. Karjagin, J., S. Lefeuvre, K. Oselin, K. Kipper, S. Marchand, A. Tikkerberi, J. Starkopf, W. Couet, and R. J. Sawchuk. 2008. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin. Pharmacol. Ther. 83:452-459.
14. Liu, P., M. Muller, M. Grant, B. Obermann, and H. Derendorf. 2005. Tissue penetration of cefpodoxime and cefixime in healthy subjects. J. Clin. Pharmacol. 45:564-569.
15. Mouton, J. W., U. Theuretzbacher, W. A. Craig, P. M. Tulkens, H. Derendorf, and O. Cars. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
16. Muller, M. 2000. Microdialysis in clinical drug delivery studies. Adv. Drug Deliv. Rev. 45:255-269.
17. Murthy, B., and A. Schmitt-Hoffmann. 2008. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47:21-33.
18. Nix, D. E., K. R. Matthias, and E. C. Ferguson. 2004. Effect of ertapenem protein binding on killing of bacteria. Antimicrob. Agents Chemother. 48:3419-3424.
19. Noel, G. J., K. Bush, P. Bagchi, J. Ianus, and R. S. Strauss. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46:647-655.
20. Noel, G. J., R. S. Strauss, K. Amsler, M. Heep, R. Pypstra, and J. S. Solomkin. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44.
21. Sauermann, R., G. Delle-Karth, C. Marsik, I. Steiner, M. Zeitlinger, B. X. Mayer-Helm, A. Georgopoulos, M. Muller, and C. Joukhadar. 2005. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob. Agents Chemother. 49:650-655.
22. Stahl, M., R. Bouw, A. Jackson, and V. Pay. 2002. Human microdialysis. Curr. Pharm. Biotechnol. 3:165-178.
23. Stahle, L., P. Arner, and U. Ungerstedt. 1991. Drug distribution studies with microdialysis. III. Extracellular concentration of caffeine in adipose tissue in man. Life Sci. 49:1853-1858.
24. Theuretzbacher, U. 2007. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr. Opin. Pharmacol. 7:498-504.
25. Zeitlinger, M., R. Sauermann, M. Fille, J. Hausdorfer, I. Leitner, and M. Muller. 2008. Plasma protein binding of fluoroquinolones affects antimicrobial activity. J. Antimicrob. Chemother. 61:561-567.